Finch Therapeutics Group, Inc.
FNCHDelisted Oct 31, 2024- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001733257
Finch Therapeutics Group, Inc. was delisted on Oct 31, 2024; its insiders filed their last Form 4 on Jun 10, 2024; no institution reported holding it in 13F filings for Q3 2024; no superinvestor held it.
Q2 2024 vs. Q1 2024
How the institutions holding Finch Therapeutics Group, Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 11 | 1 | −10 |
| Shares | 129.1K | 21.2K | −107.9K (−83.6%) |
| Value | $338.2K | $29.1K | −$309.2K (−91.4%) |
New holders (0)
Institutions that held Finch Therapeutics Group, Inc. at the end of Q2 2024 but not at the end of Q1 2024.
None.
Sold out (10)
Institutions that held Finch Therapeutics Group, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Susquehanna International Group, LLP | 59,028 | $155.2K |
| Vanguard Group Inc | 36,252 | $94.3K |
| Ikarian Capital, LLC | 6,892 | $18.1K |
| Tower Research Capital LLC (TRC) | 4,163 | $10.8K |
| Bleichroeder LP | 971 | $2.52K |
| BlackRock Inc. | 327 | $850 |
| Morgan Stanley | 156 | $406 |
| UBS Group AG | 110 | $286 |
| Wells Fargo & Company | 7 | $18 |
| Royal Bank of Canada | 27 | $0 |